Taspoglutide is a former experimental drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), that was under investigation for treatment of type 2 diabetes and being codeveloped by Ipsen and Roche.[1] [2]
| Clinical data | |
|---|---|
| Routes of administration | subcutaneous |
| ATC code |
|
| Pharmacokinetic data | |
| Bioavailability | N/A |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C152H232N40O45 |
| Molar mass | 3339.763 g·mol−1 |
  (what is this?) (verify) | |
Initially, phase II trials reported it was effective and well tolerated.[3]
Of the eight planned phase III clinical trials of weekly taspoglutide (four against exenatide, sitagliptin, insulin glargine, and pioglitazone), at least five were active in 2009.[4] Preliminary results in early 2010 were favourable.[5] (At least one of the eight planned phase III trials had not started recruiting by end 2009.[6])
In September 2010 Roche halted Phase III clinical trials due to instances of serious hypersensitivity reactions and gastrointestinal side effects.[7][8]
As of May 2022[update] no new trials have been registered since 2010.[9]
Chemistry
editTaspoglutide is the peptide with the sequence H2N-His-2-methyl-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-2-methyl-Ala-Arg-CONH2.
In other words, it is the 8-(2-methylalanine)-35-(2-methylalanine)-36-L-argininamide derivative of the amino acid sequence 7–36 of human glucagon-like peptide I.
See also
editReferences
edit- ^ "Ipsen: Roche Moves Investigational Diabetes Drug, Taspoglutide, into Phase III Clinical Trials". Business Wire. June 2008.
- ^ "Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials". June 2008. Archived from the original on 3 March 2016. Retrieved 13 January 2009.
- ^ Baggio LL, Drucker DJ (2008). "Glucagon-like Peptide-1 Analogs Other Than Exenatide".
- ^ "Ipsen's Partner Roche Announces That Taspoglutide Meets Its Primary Endpoint in the First Phase III Clinical Trial". October 2009. Archived from the original on 1 March 2010. Retrieved 12 February 2010.
- ^ "Roche Reports Positive Data from Five Phase III Trials of Type 2 Diabetes Therapy". February 2010.
- ^ Clinical trial number NCT01051011 for "A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy" at ClinicalTrials.gov
- ^ "Roche Halts Trials of Taspoglutide". 13 September 2010.
- ^ "Experimental Diabetes Drug Taspoglutide Late-Stage Trials Suspended". 13 September 2010.
- ^ Clinical studies of taspoglutide
 | This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |